Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases
Secarna’s LNAplus™ ASOs suppress expression of NLRP3, a central element of the inflammasome pathway, which is overactive in lots of ...